Other successful biomarkers such as “immunoscore” derived from quantitative measurement of tumor‐infiltrated CD3+/CD8+ T cells has already placed into the application frontline in clinics in CRC and potentially many others.224. The gene discussed is CD8A; the disease is neoplasm.